CoChat

Application of Computational Biology and Artificial Intelligence in Drug Design

Open access
Zhang, Yue, Luo, Mengqi, Wu, Peng, Wu, Song, Lee, Tzong-Yi, Bai, Chen · 2022 · International Journal of Molecular Sciences
Cited by 150

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

Traditional drug design requires a great amount of research time and developmental expense. Booming computational approaches, including computational biology, computer-aided drug design, and artificial intelligence, have the potential to expedite the efficiency of drug discovery by minimizing the time and financial cost. In recent years, computational approaches are being widely used to improve the efficacy and effectiveness of drug discovery and pipeline, leading to the approval of plenty of new drugs for marketing. The present review emphasizes on the applications of these indispensable computational approaches in aiding target identification, lead discovery, and lead optimization. Some challenges of using these approaches for drug design are also discussed. Moreover, we propose a methodology for integrating various computational techniques into new drug discovery and design.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms232113568

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Research works printed but not linked: 291

  1. Song, 2009, Recent advances in computer-aided drug design, Brief. Bioinform., 10, 579, 10.1093/bib/bbp023 · DOI · Paper page
  2. Kalyan, 2018, Pharmaceutical Medicine and Translational Clinical Research, Curr. Sci., 115, 1403
  3. Sabe, 2021, Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review, Eur. J. Med. Chem., 224, 113705, 10.1016/j.ejmech.2021.113705 · DOI · Paper page
  4. Gurung, 2021, An Updated Review of Computer-Aided Drug Design and Its Application to COVID-19, BioMed Res. Int., 2021, 8853056, 10.1155/2021/8853056 · DOI · Paper page
  5. Zhong, 2018, Artificial intelligence in drug design, Sci. China Life Sci., 61, 1191, 10.1007/s11427-018-9342-2 · DOI · Paper page
  6. Hou, 2004, Recent development and application of virtual screening in drug discovery: An overview, Curr. Pharm. Des., 10, 1011, 10.2174/1381612043452721 · DOI · Paper page
  7. Hill, R.G., and Richards, D. (2021). Drug Discovery and Development E-Book: Technology in Transition, Elsevier Health Sciences.
  8. Durrant, J.D., and McCammon, J.A. (2011). Molecular dynamics simulations and drug discovery. BMC Biol., 9. · DOI · Paper page
  9. Zhao, 2015, Molecular dynamics in drug design, Eur. J. Med. Chem., 91, 4, 10.1016/j.ejmech.2014.08.004 · DOI · Paper page
  10. Honarparvar, 2014, Integrated approach to structure-based enzymatic drug design: Molecular modeling, spectroscopy, and experimental bioactivity, Chem. Rev., 114, 493, 10.1021/cr300314q · DOI · Paper page
  11. Labanowski, J.K., and Andzelm, J.W. (2012). Density Functional Methods in Chemistry, Springer.
  12. Hafner, 2008, Ab-initio simulations of materials using VASP: Density-functional theory and beyond, J. Comput. Chem., 29, 2044, 10.1002/jcc.21057 · DOI · Paper page
  13. Chivian, 2003, Ab initio methods, Meth. Biochem. Anal., 44, 547, 10.1002/0471721204.ch27 · DOI
  14. Sebastiani, 2003, Advances in Density-Functional-Based Modeling Techniques-Recent Extensions of the Car-Parrinello Approach, Meth. Princ. Med. Chem., 17, 5
  15. Veselovsky, 2003, Strategy of computer-aided drug design, Curr. Drug Targets-Infect. Disord., 3, 33, 10.2174/1568005033342145 · doi:10.2174/1568005033342145
  16. Surabhi, 2018, Computer aided drug design: An overview, J. Drug Deliv. Ther., 8, 504, 10.22270/jddt.v8i5.1894 · DOI · Paper page
  17. Kore, 2012, Computer-aided drug design: An innovative tool for modeling, Open J. Med. Chem., 2, 139
  18. Baig, 2016, Computer aided drug design: Success and limitations, Curr. Pharm. Des., 22, 572, 10.2174/1381612822666151125000550 · DOI · Paper page
  19. Yu, W., and MacKerell, A.D. (2017). Computer-aided drug design methods. Antibiotics, Springer. · DOI · Paper page
  20. Lyne, 2002, Structure-based virtual screening: An overview, Drug Discov. Today, 7, 1047, 10.1016/S1359-6446(02)02483-2 · DOI · Paper page
  21. Lionta, 2014, Structure-based virtual screening for drug discovery: Principles, applications and recent advances, Curr. Top. Med. Chem., 14, 1923, 10.2174/1568026614666140929124445 · DOI · Paper page
  22. 2018, A review of ligand-based virtual screening web tools and screening algorithms in large molecular databases in the age of big data, Future Med. Chem., 10, 2641, 10.4155/fmc-2018-0076 · DOI
  23. Lavecchia, 2013, Virtual screening strategies in drug discovery: A critical review, Curr. Med. Chem., 20, 2839, 10.2174/09298673113209990001 · DOI · Paper page
  24. Sohraby, F., Bagheri, M., and Aryapour, H. (2019). Performing an in silico repurposing of existing drugs by combining virtual screening and molecular dynamics simulation. Computational Methods for Drug Repurposing, Springer. · DOI
  25. Issa, 2013, Drug repurposing a reality: From computers to the clinic, Expert Rev. Clin. Pharmacol., 6, 95, 10.1586/ecp.12.79 · DOI
  26. Duch, 2007, Artificial intelligence approaches for rational drug design and discovery, Curr. Pharm. Des., 13, 1497, 10.2174/138161207780765954 · DOI · Paper page
  27. Gertrudes, 2012, Machine learning techniques and drug design, Curr. Med. Chem., 19, 4289, 10.2174/092986712802884259 · DOI · Paper page
  28. Lima, 2016, Use of machine learning approaches for novel drug discovery, Expert Opin. Drug Discov., 11, 225, 10.1517/17460441.2016.1146250 · DOI · Paper page
  29. Klambauer, 2019, Machine Learning in Drug Discovery, J. Chem. Inf. Model., 59, 945, 10.1021/acs.jcim.9b00136 · DOI · Paper page
  30. Carpenter, 2018, Machine learning-based virtual screening and its applications to Alzheimer’s drug discovery: A review, Curr. Pharm. Des., 24, 3347, 10.2174/1381612824666180607124038 · DOI · Paper page
  31. Mendolia, I., Contino, S., Perricone, U., Ardizzone, E., and Pirrone, R. (2020). Convolutional architectures for virtual screening. BMC Bioinform., 21. · DOI
  32. Bohr, H. (2020). Drug discovery and molecular modeling using artificial intelligence. Artificial Intelligence in Healthcare, Elsevier. · DOI
  33. Gimeno, A., Ojeda-Montes, M.J., Tomás-Hernández, S., Cereto-Massagué, A., Beltrán-Debón, R., Mulero, M., Pujadas, G., and Garcia-Vallvé, S. (2019). The light and dark sides of virtual screening: What is there to know?. Int. J. Mol. Sci., 20. · DOI · Paper page
  34. Liu, 2018, Molecular dynamics simulations and novel drug discovery, Expert Opin. Drug Discov., 13, 23, 10.1080/17460441.2018.1403419 · DOI · Paper page
  35. Yan, 2022, The advanced development of molecular targeted therapy for hepatocellular carcinoma, Cancer Biol. Med., 19, 802, 10.20892/j.issn.2095-3941.2021.0661 · DOI
  36. Boomsma, 2016, Bioinformatics analysis identifies several intrinsically disordered human E3 ubiquitin-protein ligases, PeerJ, 4, e1725, 10.7717/peerj.1725 · DOI
  37. Xia, 2017, Bioinformatics and drug discovery, Curr. Top. Med. Chem., 17, 1709, 10.2174/1568026617666161116143440 · DOI · Paper page
  38. Huang, 2021, AURKB, CHEK1 and NEK2 as the Potential Target Proteins of Scutellaria barbata on Hepatocellular Carcinoma: An Integrated Bioinformatics Analysis, Int. J. Gen. Med., 14, 3295, 10.2147/IJGM.S318077 · doi:10.2147/ijgm.s318077
  39. Gordon, 2020, Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms, Science, 370, eabe9403, 10.1126/science.abe9403 · DOI · Paper page
  40. Chen, 2020, Target identification of natural medicine with chemical proteomics approach: Probe synthesis, target fishing and protein identification, Signal Transduct. Target. Ther., 5, 72, 10.1038/s41392-020-0186-y · DOI · Paper page
  41. Guo, 2012, Influence of the pathogenic mutations T188K/R/A on the structural stability and misfolding of human prion protein: Insight from molecular dynamics simulations, Biochim. Biophys. Acta Gen. Subj., 1820, 116, 10.1016/j.bbagen.2011.11.013 · DOI
  42. Hansson, 2002, Molecular dynamics simulations, Curr. Opin. Struct. Biol., 12, 190, 10.1016/S0959-440X(02)00308-1 · DOI · Paper page
  43. Hasan, 2020, Design and synthesis of graphene oxide-based glass substrate and its antimicrobial activity against MDR Bacterial Pathogens, J. Mech. Eng. Res. Dev., 43, 11
  44. Barone, 2004, Computation of protein pK’s values by an integrated density functional theory/polarizable continuum model approach, Theor. Chem. Acc., 111, 237, 10.1007/s00214-003-0541-4 · doi:10.1007/s00214-003-0541-4
  45. Souza, 2019, An allosteric pathway in copper, zinc superoxide dismutase unravels the molecular mechanism of the G93A amyotrophic lateral sclerosis-linked mutation, J. Phys. Chem. Lett., 10, 7740, 10.1021/acs.jpclett.9b02868 · DOI · Paper page
  46. Moreira, 2016, Reaction mechanism of Mycobacterium Tuberculosis glutamine synthetase using quantum mechanics/molecular mechanics calculations, Chem. A Eur. J., 22, 9218, 10.1002/chem.201600305 · doi:10.1002/chem.201600305
  47. Peters, 2006, Quantum mechanics in structure-based drug design, Curr. Opin. Drug Discov. Dev., 9, 370
  48. Barman, T.K., Hazarika, A.K., Kalita, U., Dhar, R., Borah, L., Chetri, S., and Ghosh, S.S. (2022). Epidemiology of Anti-HIV Drug Resistance: Quantum Mechanics (Qm) and Molecular Mechanics (MM) Studies into the Binding of 6-Aminoquinoline Molecules within HIV Protein (1AJX) and Its Economic Implication, Elsevier. · DOI
  49. Xu, 2005, Antibiotic Binding to Monozinc CphA β-Lactamase from Aeromonas hydropila: Quantum Mechanical/Molecular Mechanical and Density Functional Theory Studies, J. Med. Chem., 48, 6679, 10.1021/jm0505112 · doi:10.1021/jm0505112
  50. Hassan, 2022, Exploring the bioactive sites of new sulfonamide metal chelates for multi-drug resistance: An experimental versus theoretical design, J. Inorg. Organomet. Polym. Mater., 32, 513, 10.1007/s10904-021-02135-6 · DOI
  51. Ode, 2007, Mechanism of drug resistance due to N88S in CRF01_AE HIV-1 protease, analyzed by molecular dynamics simulations, J. Med. Chem., 50, 1768, 10.1021/jm061158i · DOI
  52. Amusengeri, A., Tata, R.B., and Bishop, Ö.T. (2020). Understanding the pyrimethamine drug resistance mechanism via combined molecular dynamics and dynamic residue network analysis. Molecules, 25. · DOI
  53. Vanommeslaeghe, 2014, Molecular mechanics, Curr. Pharm. Des., 20, 3281, 10.2174/13816128113199990600 · DOI
  54. Bekono, B.D., Sona, A.N., Eni, D.B., Owono, L.C., Megnassan, E., and Ntie-Kang, F. (2021). Molecular mechanics approaches for rational drug design: Forcefields and solvation models. Phys. Sci. Rev., 20190128. · doi:10.1515/9783110682045-013
  55. Yuriev, 2018, Free Energy Methods in Drug Design: Prospects of “Alchemical Perturbation” in Medicinal Chemistry, J. Med. Chem., 61, 638, 10.1021/acs.jmedchem.7b00681 · DOI · Paper page
  56. Allen, 2004, Introduction to molecular dynamics simulation, Comput. Soft Matter: Synth. Polym. Proteins, 23, 1
  57. Moroy, 2015, Sampling of conformational ensemble for virtual screening using molecular dynamics simulations and normal mode analysis, Future Med. Chem., 7, 2317, 10.4155/fmc.15.150 · DOI
  58. Berman, 2000, The protein data bank, Nucleic Acids Res., 28, 235, 10.1093/nar/28.1.235 · DOI · Paper page
  59. Whittig, 1986, X-ray diffraction techniques, Meth. Soil Anal. Part 1 Phys. Mineral. Meth., 5, 331
  60. Javier, 2020, Cryo-Electron Microscopy: Moving Beyond X-Ray Crystal Structures for Drug Receptors and Drug Development, Ann. Rev. Pharmacol. Toxicol., 60, 51, 10.1146/annurev-pharmtox-010919-023545 · DOI
  61. Bai, 2015, How cryo-EM is revolutionizing structural biology, Trends Biochem. Sci., 40, 49, 10.1016/j.tibs.2014.10.005 · DOI · Paper page
  62. Weissenberger, 2021, Understanding the invisible hands of sample preparation for cryo-EM, Nat. Methods, 18, 463, 10.1038/s41592-021-01130-6 · DOI · Paper page
  63. Krieger, 2003, Homology modeling, Meth. Biochem. Anal., 44, 509, 10.1002/0471721204.ch25 · DOI · Paper page
  64. Cavasotto, 2009, Homology modeling in drug discovery: Current trends and applications, Drug Discov. Today, 14, 676, 10.1016/j.drudis.2009.04.006 · DOI · Paper page
  65. AlQuraishi, 2019, AlphaFold at CASP13, Bioinformatics, 35, 4862, 10.1093/bioinformatics/btz422 · DOI · Paper page
  66. MacKerell, A.D. (2001). Atomistic models and force fields. Computational Biochemistry and Biophysics, CRC Press. · doi:10.1201/9780203903827.ch2
  67. Robertson, 2015, Improved peptide and protein torsional energetics with the OPLS-AA force field, J. Chem. Theory Comput., 11, 3499, 10.1021/acs.jctc.5b00356 · DOI · Paper page
  68. Hagler, 2019, Biomolecular force fields: Where have we been, where are we now, where do we need to go and how do we get there?, J. Comput. Aided Mol. Des., 33, 133, 10.1007/s10822-018-0111-4 · DOI
  69. Lee, 2017, Validating a Coarse-Grained Voltage Activation Model by Comparing Its Performance to the Results of Monte Carlo Simulations, J. Phys. Chem. B, 121, 11284, 10.1021/acs.jpcb.7b09530 · DOI
  70. Vorobyov, 2016, Refining the treatment of membrane proteins by coarse-grained models, Proteins: Struct. Funct. Bioinform., 84, 92, 10.1002/prot.24958 · DOI
  71. Horikoshi, 2021, Long-range structural defects by pathogenic mutations in most severe glucose-6-phosphate dehydrogenase deficiency, Proc. Natl. Acad. Sci. USA, 118, e2022790118, 10.1073/pnas.2022790118 · DOI
  72. Budaitis, 2021, Pathogenic mutations in the kinesin-3 motor KIF1A diminish force generation and movement through allosteric mechanisms, J. Cell Biol., 220, e202004227, 10.1083/jcb.202004227 · DOI · Paper page
  73. Korovesis, 2018, The architecture of EGFR’s basal complexes reveals autoinhibition mechanisms in dimers and oligomers, Nat. Commun., 9, 4325, 10.1038/s41467-018-06632-0 · DOI
  74. Zhu, M., Wang, D.D., and Yan, H. (2021). Genotype-determined EGFR-RTK heterodimerization and its effects on drug resistance in lung Cancer treatment revealed by molecular dynamics simulations. BMC Mol. Cell Biol., 22. · DOI
  75. Tyni, 2018, Natural polyphenols as sirtuin 6 modulators, Sci. Rep., 8, 4163, 10.1038/s41598-018-22388-5 · DOI · Paper page
  76. Jiang, 2022, An Intelligent Strategy with All-Atom Molecular Dynamics Simulations for the Design of Lipopeptides against Multidrug-Resistant Pseudomonas aeruginosa, J. Med. Chem., 65, 10001, 10.1021/acs.jmedchem.2c00657 · DOI
  77. Cavasotto, 2007, Ligand docking and structure-based virtual screening in drug discovery, Curr. Top. Med. Chem., 7, 1006, 10.2174/156802607780906753 · DOI · Paper page
  78. Kitchen, 2004, Docking and scoring in virtual screening for drug discovery: Methods and applications, Nat. Rev. Drug Discov., 3, 935, 10.1038/nrd1549 · DOI · Paper page
  79. Keseru, 2011, Integration of virtual and high throughput screening in lead discovery settings, Comb. Chem. High Throughput Screen., 14, 889, 10.2174/138620711797537148 · DOI
  80. Hu, 2013, Inhibitors of the Yersinia protein tyrosine phosphatase through high throughput and virtual screening approaches, Bioorganic Med. Chem. Lett., 23, 1056, 10.1016/j.bmcl.2012.12.018 · doi:10.1016/j.bmcl.2012.12.018
  81. Lee, 2014, Identification of novel drug scaffolds for inhibition of SARS-CoV 3-Chymotrypsin-like protease using virtual and high-throughput screenings, Bioorganic Med. Chem., 22, 167, 10.1016/j.bmc.2013.11.041 · DOI
  82. Cheng, 2012, Structure-based virtual screening for drug discovery: A problem-centric review, AAPS J., 14, 133, 10.1208/s12248-012-9322-0 · DOI · Paper page
  83. Sastry, 2013, Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments, J. Comput. Aided Mol. Des., 27, 221, 10.1007/s10822-013-9644-8 · DOI · Paper page
  84. Sliwoski, 2014, Computational methods in drug discovery, Pharmacol. Rev., 66, 334, 10.1124/pr.112.007336 · DOI · Paper page
  85. Taylor, 2002, A review of protein-small molecule docking methods, J. Comput. Aided Mol. Des., 16, 151, 10.1023/A:1020155510718 · DOI · Paper page
  86. Stahl, 2003, Binding site characteristics in structure-based virtual screening: Evaluation of current docking tools, J. Mol. Model., 9, 47, 10.1007/s00894-002-0112-y · DOI · Paper page
  87. Cross, 2009, Comparison of several molecular docking programs: Pose prediction and virtual screening accuracy, J. Chem. Inf. Model., 49, 1455, 10.1021/ci900056c · DOI · Paper page
  88. Kumar, 2021, In silico virtual screening-based study of nutraceuticals predicts the therapeutic potentials of folic acid and its derivatives against COVID-19, VirusDisease, 32, 29, 10.1007/s13337-020-00643-6 · DOI
  89. Pantsar, T., and Poso, A. (2018). Binding affinity via docking: Fact and fiction. Molecules, 23. · DOI · Paper page
  90. Macip, 2022, Haste makes waste: A critical review of docking-based virtual screening in drug repurposing for SARS-CoV-2 main protease (M-pro) inhibition, Med. Res. Rev., 42, 744, 10.1002/med.21862 · DOI
  91. Murugan, N.A., Podobas, A., Gadioli, D., Vitali, E., Palermo, G., and Markidis, S. (2022). A review on parallel virtual screening softwares for high-performance computers. Pharmaceuticals, 15. · DOI
  92. Rastelli, 2019, Refinement and Rescoring of Virtual Screening Results, Front. Chem., 7, 498, 10.3389/fchem.2019.00498 · DOI
  93. Salmaso, 2018, Bridging molecular docking to molecular dynamics in exploring ligand-protein recognition process: An overview, Front. Pharmacol., 9, 923, 10.3389/fphar.2018.00923 · DOI · Paper page
  94. Liu, W., Schmidt, B., Voss, G., and Müller-Wittig, W. (2007, January 18–21). Molecular dynamics simulations on commodity GPUs with CUDA. Proceedings of the International Conference on High-Performance Computing, Goa, India.
  95. Ramalingam, 1996, On the computational complexity of dynamic graph problems, Theor. Comput. Sci., 158, 233, 10.1016/0304-3975(95)00079-8 · DOI
  96. Gotz, 2013, Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent particle mesh Ewald, J. Chem. Theory Comput., 9, 3878, 10.1021/ct400314y · DOI · Paper page
  97. Genheden, 2015, The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities, Expert Opin. Drug Discov., 10, 449, 10.1517/17460441.2015.1032936 · DOI · Paper page
  98. Ahmad, 2021, Optimizing Bedaquiline for cardiotoxicity by structure based virtual screening, DFT analysis and molecular dynamic simulation studies to identify selective MDR-TB inhibitors, Silico Pharmacol., 9, 23, 10.1007/s40203-021-00086-x · DOI
  99. Castillo, 2019, In silico hit optimization toward AKT inhibition: Fragment-based approach, molecular docking and molecular dynamics study, J. Biomol. Struct. Dyn., 37, 4301, 10.1080/07391102.2018.1546618 · doi:10.1080/07391102.2018.1546618
  100. Zhang, 2017, Discovery of Novel Phosphodiesterase-2A Inhibitors by Structure-Based Virtual Screening, Structural Optimization, and Bioassay, J. Chem. Inf. Model., 57, 355, 10.1021/acs.jcim.6b00551 · DOI
  101. Ruskamo, 2014, Atomic resolution view into the structure–function relationships of the human myelin peripheral membrane protein P2, Acta Crystallogr. Sect. D: Biol.Crystallogr., 70, 165, 10.1107/S1399004713027910 · DOI · Paper page
  102. Kmiecik, 2016, Coarse-grained protein models and their applications, Chem. Rev., 116, 7898, 10.1021/acs.chemrev.6b00163 · DOI · Paper page
  103. Singh, N., and Li, W. (2019). Recent advances in coarse-grained models for biomolecules and their applications. Int. J. Mol. Sci., 20. · DOI
  104. Vicatos, 2014, An effective Coarse-grained model for biological simulations: Recent refinements and validations, Proteins: Struct. Funct. Bioinform., 82, 1168, 10.1002/prot.24482 · DOI
  105. Bai, 2021, Predicting Mutational Effects on Receptor Binding of the Spike Protein of SARS-CoV-2 Variants, J. Am. Chem. Soc., 143, 17646, 10.1021/jacs.1c07965 · DOI
  106. Bai, 2021, Exploring the Activation Process of the β2AR-Gs Complex, J. Am. Chem. Soc., 143, 11044, 10.1021/jacs.1c03696 · DOI
  107. Mukherjee, 2011, Electrostatic origin of the mechanochemical rotary mechanism and the catalytic dwell of F1-ATPase, Proc. Natl. Acad. Sci. USA, 108, 20550, 10.1073/pnas.1117024108 · DOI
  108. Bai, 2019, Revisiting the protomotive vectorial motion of F0-ATPase, Proc. Natl. Acad. Sci. USA, 116, 19484, 10.1073/pnas.1909032116 · doi:10.1073/pnas.1909032116
  109. Zhang, 2012, Dissecting the kinematics of the kinesin step, Structure, 20, 628, 10.1016/j.str.2012.02.013 · DOI
  110. Warshel, 2006, Modeling electrostatic effects in proteins, Biochim. Biophys. Acta Proteins Proteom., 1764, 1647, 10.1016/j.bbapap.2006.08.007 · DOI · Paper page
  111. Marrone, 1997, Structure-based drug design: Computational advances, Annu. Rev. Pharmacol. Toxicol., 37, 71, 10.1146/annurev.pharmtox.37.1.71 · DOI
  112. Raha, 2007, The role of quantum mechanics in structure-based drug design, Drug Discov. Today, 12, 725, 10.1016/j.drudis.2007.07.006 · DOI · Paper page
  113. Enyedy, 2008, Can we use docking and scoring for hit-to-lead optimization?, J. Comput. Aided Mol. Des., 22, 161, 10.1007/s10822-007-9165-4 · DOI
  114. Guterres, 2020, Improving protein-ligand docking results with high-throughput molecular dynamics simulations, J. Chem. Inf. Model., 60, 2189, 10.1021/acs.jcim.0c00057 · DOI · Paper page
  115. Berishvili, V., Kuimov, A., Voronkov, A., Radchenko, E., Kumar, P., Choonara, Y., Pillay, V., Kamal, A., and Palyulin, V. (2020). Discovery of novel tankyrase inhibitors through molecular docking-based virtual screening and molecular dynamics simulation studies. Molecules, 25. · DOI
  116. Halgren, 2001, Polarizable force fields, Curr. Opin. Struct. Biol., 11, 236, 10.1016/S0959-440X(00)00196-2 · DOI · Paper page
  117. Arodola, 2017, Quantum mechanics implementation in drug-design workflows: Does it really help?, Drug Des. Dev. Ther., 11, 2551, 10.2147/DDDT.S126344 · DOI
  118. Ribeiro, 2015, Enzymatic flexibility and reaction rate: A QM/MM study of HIV-1 protease, ACS Catal., 5, 5617, 10.1021/acscatal.5b00759 · DOI
  119. Uddin, 2019, Halogenated derivatives of methotrexate as human dihydrofolate reductase inhibitors in cancer chemotherapy, J. Biomol. Struct. Dyn., 38, 901, 10.1080/07391102.2019.1591302 · DOI
  120. Nakliang, P., Lazim, R., Chang, H., and Choi, S. (2020). Multiscale molecular modeling in G protein-coupled receptor (GPCR)-ligand studies. Biomolecules, 10. · DOI
  121. Zhou, 2010, Catalytic reaction mechanism of acetylcholinesterase determined by Born-Oppenheimer ab initio QM/MM molecular dynamics simulations, J. Phys. Chem. B, 114, 8817, 10.1021/jp104258d · DOI · Paper page
  122. Chen, 2011, Reaction pathway and free energy profile for butyrylcholinesterase-catalyzed hydrolysis of acetylcholine, J. Phys. Chem. B, 115, 1315, 10.1021/jp110709a · doi:10.1021/jp110709a
  123. Cheng, 2007, Acetylcholinesterase: Mechanisms of covalent inhibition of wild-type and H447I mutant determined by computational analyses, J. Am. Chem. Soc., 129, 6562, 10.1021/ja070601r · DOI
  124. Liu, 2009, Reaction pathway and free-energy barrier for reactivation of dimethylphosphoryl-inhibited human acetylcholinesterase, J. Phys. Chem. B, 113, 16226, 10.1021/jp9055335 · DOI
  125. Olivieri, L., and Gardebien, F. (2014). Structure-affinity properties of a high-affinity ligand of FKBP12 studied by molecular simulations of a binding intermediate. PLoS ONE, 9. · doi:10.1371/journal.pone.0114610
  126. Tosso, 2013, Molecular modeling study of dihydrofolate reductase inhibitors. Molecular dynamics simulations, quantum mechanical calculations, and experimental corroboration, J. Chem. Inf. Model., 53, 2018, 10.1021/ci400178h · DOI
  127. Cho, 2005, Importance of accurate charges in molecular docking: Quantum mechanical/molecular mechanical (QM/MM) approach, J. Comput. Chem., 26, 915, 10.1002/jcc.20222 · DOI · Paper page
  128. Raha, 2005, Large-scale validation of a quantum mechanics based scoring function: Predicting the binding affinity and the binding mode of a diverse set of protein-ligand complexes, J. Med. Chem., 48, 4558, 10.1021/jm048973n · DOI · Paper page
  129. Gleeson, 2009, QM/MM calculations in drug discovery: A useful method for studying binding phenomena?, J. Chem. Inf. Model., 49, 670, 10.1021/ci800419j · DOI
  130. Zhang, 2012, Recent development in quantum mechanics/molecular mechanics modeling for materials, Int. J. Multiscale Comput. Eng., 10, 65
  131. Cavasotto, 2018, Quantum chemical approaches in structure-based virtual screening and lead optimization, Front. Chem., 6, 188, 10.3389/fchem.2018.00188 · DOI
  132. Fong, 2009, Assessment of QM/MM scoring functions for molecular docking to HIV-1 protease, J. Chem. Inf. Model., 49, 913, 10.1021/ci800432s · DOI
  133. Kim, 2016, Incorporating QM and solvation into docking for applications to GPCR targets, Phys. Chem. Chem. Phys., 18, 28281, 10.1039/C6CP04742D · DOI
  134. Latorre, 2004, Universality of entanglement and quantum-computation complexity, Phys. Rev. A, 69, 052308, 10.1103/PhysRevA.69.052308 · DOI · Paper page
  135. Senn, 2009, QM/MM methods for biomolecular systems, Angew. Chem. Int. Ed., 48, 1198, 10.1002/anie.200802019 · DOI · Paper page
  136. Wilson, E., Vant, J., Layton, J., Boyd, R., Lee, H., Turilli, M., Hernández, B., Wilkinson, S., Jha, S., and Gupta, C. (2021). Large-Scale Molecular Dynamics Simulations of Cellular Compartments. Structure and Function of Membrane Proteins, Springer. · DOI
  137. Hoque, 2017, An approach of computer-aided drug design (CADD) tools for in silico pharmaceutical drug design and development, Int. J. Adv. Res. Biol. Sci., 4, 60, 10.22192/ijarbs.2017.04.02.009 · DOI
  138. McKenna, 1983, Captopril, Br. Med. J., 287, 1299, 10.1136/bmj.287.6401.1299 · doi:10.1136/bmj.287.6401.1299
  139. 2021, Drug repurposing: A strategy for discovering inhibitors against emerging viral infections, Curr. Med. Chem., 28, 2887, 10.2174/0929867327666200812215852 · DOI
  140. Huang, 2010, Current developments of computer-aided drug design, J. Taiwan Instit. Chem. Eng., 41, 623, 10.1016/j.jtice.2010.03.017 · DOI
  141. Druker, 2000, Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia, J. Clin. Investig., 105, 3, 10.1172/JCI9083 · DOI · Paper page
  142. 2007, Computer-aided drug design: The next 20 years, J. Comput. Aided Mol. Des., 21, 591, 10.1007/s10822-007-9142-y · DOI · Paper page
  143. Gervasio, 2018, From computers to bedside: Computational chemistry contributing to FDA approval, Biomolecular Simulations in Structure-Based Drug Discover, Volume 75, 163
  144. Macalino, S.J.Y., Basith, S., Clavio, N.A.B., Chang, H., Kang, S., and Choi, S. (2018). Evolution of in silico strategies for protein-protein interaction drug discovery. Molecules, 23. · DOI
  145. Wang, 2018, Structure-based drug design strategies and challenges, Curr. Top. Med. Chem., 18, 998, 10.2174/1568026618666180813152921 · DOI
  146. Lerner, 2021, FRET-based dynamic structural biology: Challenges, perspectives and an appeal for open-science practices, Elife, 10, e60416, 10.7554/eLife.60416 · DOI · Paper page
  147. Lee, J., Freddolino, P.L., and Zhang, Y. (2017). Ab initio protein structure prediction. From Protein Structure to Function with Bioinformatics, Springer. · DOI
  148. Pan, 2017, Identification of the tolfenamic acid binding pocket in PrbP from Liberibacter asiaticus, Front. Microbiol., 8, 1591, 10.3389/fmicb.2017.01591 · DOI
  149. 2006, Blind docking of drug-sized compounds to proteins with up to a thousand residues, FEBS Lett., 580, 1447, 10.1016/j.febslet.2006.01.074 · DOI · Paper page
  150. Hassan, 2017, Protein-ligand blind docking using QuickVina-W with inter-process spatio-temporal integration, Sci. Rep., 7, 15451, 10.1038/s41598-017-15571-7 · DOI · Paper page
  151. Liu, 2020, CB-Dock: A web server for cavity detection-guided protein-ligand blind docking, Acta Pharmacol. Sin., 41, 138, 10.1038/s41401-019-0228-6 · DOI · Paper page
  152. 2002, Efficient docking of peptides to proteins without prior knowledge of the binding site, Protein Sci., 11, 1729, 10.1110/ps.0202302 · DOI · Paper page
  153. Iorga, 2006, Acetylcholine nicotinic receptors: Finding the putative binding site of allosteric modulators using the “blind docking” approach, J. Mol. Model., 12, 366, 10.1007/s00894-005-0057-z · DOI
  154. Liang, 2020, Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface, Comput. Biol. Chem., 89, 107372, 10.1016/j.compbiolchem.2020.107372 · DOI
  155. Doerr, 2017, DeepSite: Protein-binding site predictor using 3D-convolutional neural networks, Bioinformatics, 33, 3036, 10.1093/bioinformatics/btx350 · DOI · Paper page
  156. Volkamer, 2012, Combining global and local measures for structure-based druggability predictions, J. Chem. Inf. Model., 52, 360, 10.1021/ci200454v · DOI · Paper page
  157. Yu, 2010, Roll: A new algorithm for the detection of protein pockets and cavities with a rolling probe sphere, Bioinformatics, 26, 46, 10.1093/bioinformatics/btp599 · DOI · Paper page
  158. Schmidtke, 2010, Fpocket: Online tools for protein ensemble pocket detection and tracking, Nucleic Acids Res., 38, W582, 10.1093/nar/gkq383 · DOI · Paper page
  159. Bruno, 2016, The chemosensitizing agent lubeluzole binds calmodulin and inhibits Ca2+/calmodulin-dependent kinase II, Eur. J. Med. Chem., 116, 36, 10.1016/j.ejmech.2016.03.045 · DOI
  160. Wang, 2016, RaptorX-Property: A web server for protein structure property prediction, Nucleic Acids Res., 44, W430, 10.1093/nar/gkw306 · DOI · Paper page
  161. Yang, 2013, Protein-ligand binding site recognition using complementary binding-specific substructure comparison and sequence profile alignment, Bioinformatics, 29, 2588, 10.1093/bioinformatics/btt447 · DOI · Paper page
  162. Kalidas, 2008, PocketDepth: A new depth based algorithm for identification of ligand binding sites in proteins, J. Struct. Biol., 161, 31, 10.1016/j.jsb.2007.09.005 · DOI
  163. Gorgulla, 2020, An open-source drug discovery platform enables ultra-large virtual screens, Nature, 580, 663, 10.1038/s41586-020-2117-z · DOI · Paper page
  164. Irwin, 2012, ZINC: A free tool to discover chemistry for biology, J. Chem. Inf. Model, 52, 1757, 10.1021/ci3001277 · DOI · Paper page
  165. Kiss, 2012, http://Mcule.com: A public web service for drug discovery, J. Cheminform., 4, P17, 10.1186/1758-2946-4-S1-P17 · DOI · Paper page
  166. Wishart, 2008, DrugBank: A knowledgebase for drugs, drug actions and drug targets, Nucleic Acids Res., 36, D901, 10.1093/nar/gkm958 · DOI · Paper page
  167. Gaulton, 2017, The ChEMBL database in 2017, Nucleic Acids Res., 45, D945, 10.1093/nar/gkw1074 · DOI · Paper page
  168. Chen, 2005, ChemDB: A public database of small molecules and related chemoinformatics resources, Bioinformatics, 21, 4133, 10.1093/bioinformatics/bti683 · DOI · Paper page
  169. Lipinski, 2004, Lead- and drug-like compounds: The rule-of-five revolution, Drug Discov. Today: Technol., 1, 337, 10.1016/j.ddtec.2004.11.007 · DOI · Paper page
  170. Whitty, 2016, Quantifying the chameleonic properties of macrocycles and other high-molecular-weight drugs, Drug Discov. Today, 21, 712, 10.1016/j.drudis.2016.02.005 · DOI · Paper page
  171. Huang, 2010, Advances and challenges in protein-ligand docking, Int. J. Mol. Sci., 11, 3016, 10.3390/ijms11083016 · DOI · Paper page
  172. Morris, 2009, AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility, J. Comput. Chem., 30, 2785, 10.1002/jcc.21256 · DOI · Paper page
  173. Wu, 2003, Detailed analysis of grid-based molecular docking: A case study of CDOCKER—A CHARMm-based MD docking algorithm, J. Comput. Chem., 24, 1549, 10.1002/jcc.10306 · DOI · Paper page
  174. Allen, 2015, DOCK 6: Impact of new features and current docking performance, J. Comput. Chem., 36, 1132, 10.1002/jcc.23905 · DOI · Paper page
  175. Kramer, 1999, Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking, Proteins: Struct. Funct. Bioinform., 37, 228, 10.1002/(SICI)1097-0134(19991101)37:2<228::AID-PROT8>3.0.CO;2-8 · DOI · Paper page
  176. Berry, 2015, Practical considerations in virtual screening and molecular docking, Emerg. Trends Comput. Biol. Bioinform. Syst. Biol., 1762, 487
  177. Yadava, 2018, Search algorithms and scoring methods in protein-ligand docking, Endocrinol. Metab. Int. J., 6, 359, 10.15406/emij.2018.06.00212 · DOI
  178. Hart, 1992, A multiple-start Monte Carlo docking method, Proteins: Struct. Funct. Bioinform., 13, 206, 10.1002/prot.340130304 · DOI · Paper page
  179. Oshiro, 1995, Flexible ligand docking using a genetic algorithm, J. Comput. Aided Mol. Des., 9, 113, 10.1007/BF00124402 · DOI · Paper page
  180. Li, 2019, An overview of scoring functions used for protein–ligand interactions in molecular docking, Interdiscip. Sci.: Comput. Life Sci., 11, 320, 10.1007/s12539-019-00327-w · DOI · Paper page
  181. Stärk, H., Ganea, O., Pattanaik, L., Barzilay, R., and Jaakkola, T. (2022, January 17–23). Equibind: Geometric deep learning for drug binding structure prediction. Proceedings of the International Conference on Machine Learning, Baltimore, MD, USA.
  182. McNutt, 2021, GNINA 1.0: Molecular docking with deep learning, J. Cheminformatics, 13, 43, 10.1186/s13321-021-00522-2 · DOI · Paper page
  183. Corso, G., Stärk, H., Jing, B., Barzilay, R., and Jaakkola, T. (2022). DiffDock: Diffusion Steps, Twists, and Turns for Molecular Docking. arXiv.
  184. Salsbury, 2010, Molecular dynamics simulations of protein dynamics and their relevance to drug discovery, Curr. Opin. Pharmacol., 10, 738, 10.1016/j.coph.2010.09.016 · DOI · Paper page
  185. Ferreira, 2015, Molecular docking and structure-based drug design strategies, Molecules, 20, 13384, 10.3390/molecules200713384 · DOI · Paper page
  186. Caflisch, 2018, Protein structure-based drug design: From docking to molecular dynamics, Curr. Opin. Struct. Biol., 48, 93, 10.1016/j.sbi.2017.10.010 · DOI · Paper page
  187. Philip, 2007, Computer-aided drug design: Integration of structure-based and ligand-based approaches in drug design, Curr. Comput. Aided Drug Des., 3, 133, 10.2174/157340907780809516 · DOI
  188. Schaller, 2020, Next generation 3D pharmacophore modeling, Wiley Interdiscip. Rev.: Comput. Mol. Sci., 10, e1468
  189. 2013, Generation of three-dimensional pharmacophore models, Wiley Interdiscip. Rev.: Comput. Mol. Sci., 3, 449
  190. Yang, 2010, Pharmacophore modeling and applications in drug discovery: Challenges and recent advances, Drug Discov. Today, 15, 444, 10.1016/j.drudis.2010.03.013 · DOI · Paper page
  191. Barnum, 1996, Identification of common functional configurations among molecules, J. Chem. Inf. Comput. Sci., 36, 563, 10.1021/ci950273r · DOI · Paper page
  192. Wolber, 2005, LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters, J. Chem. Inf. Model., 45, 160, 10.1021/ci049885e · DOI · Paper page
  193. Chen, 2008, Conformational sampling of druglike molecules with MOE and catalyst: Implications for pharmacophore modeling and virtual screening, J. Chem. Inf. Model., 48, 1773, 10.1021/ci800130k · DOI
  194. Liu, 2010, PharmMapper server: A web server for potential drug target identification using pharmacophore mapping approach, Nucleic Acids Res., 38, W609, 10.1093/nar/gkq300 · DOI · Paper page
  195. Dror, 2008, PharmaGist: A webserver for ligand-based pharmacophore detection, Nucleic Acids Res., 36, W223, 10.1093/nar/gkn187 · doi:10.1093/nar/gkn187
  196. Dixon, 2006, PHASE: A novel approach to pharmacophore modeling and 3D database searching, Chem. Biol. Drug Des., 67, 370, 10.1111/j.1747-0285.2006.00384.x · DOI · Paper page
  197. Mallik, 2005, Development of a quasi-dynamic pharmacophore model for anti-complement peptide analogues, J. Am. Chem. Soc., 127, 10967, 10.1021/ja051004c · doi:10.1021/ja051004c
  198. Langer, 2004, Pharmacophore definition and 3D searches, Drug Discov. Today: Technol., 1, 203, 10.1016/j.ddtec.2004.11.015 · DOI
  199. Braga, 2014, 3D-QSAR approaches in drug design: Perspectives to generate reliable CoMFA models, Curr. Comput. Aided Drug Des., 10, 148, 10.2174/1573409910666140410111043 · DOI
  200. Verma, 2010, 3D-QSAR in drug design—A review, Curr. Top. Med. Chem., 10, 95, 10.2174/156802610790232260 · DOI · Paper page

200 of 291 shown

Cited by

Metadata

Authors
Zhang, Y., Luo, M., Wu, P., Wu, S., Lee, T.-Y., & Bai, C.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-11-05
Volume
23
Issue
21
Pages
13568
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4308510076
Cited by
150
References
38
FWCI
14.82
Type
journal article
Language
en
Open access
gold
Funders
  • National Natural Science Foundation of Youth Fund Project (22103066, 20210316202830001, C10120180043)
  • 2021 Basic Research General Project of Shenzhen, China (22103066, 20210316202830001, C10120180043)
  • Warshel Institute for Computational Biology at the Chinese University of Hong Kong, Shenzhen (22103066, 20210316202830001, C10120180043)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.